AbbVie Inc (ABBV) : Vigilant Capital Management reduced its stake in AbbVie Inc by 2.31% during the most recent quarter end. The investment management company now holds a total of 139,875 shares of AbbVie Inc which is valued at $8,869,474 after selling 3,305 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Jul 18, 2016.AbbVie Inc makes up approximately 1.65% of Vigilant Capital Management’s portfolio.
Other Hedge Funds, Including , First National Bank Of Mount Dora Trust Investment Services boosted its stake in ABBV in the latest quarter, The investment management firm added 1,452 additional shares and now holds a total of 59,290 shares of AbbVie Inc which is valued at $3,759,579. AbbVie Inc makes up approx 2.08% of First National Bank Of Mount Dora Trust Investment Services’s portfolio.Arcadia Investment Management Corpmi boosted its stake in ABBV in the latest quarter, The investment management firm added 22,116 additional shares and now holds a total of 90,900 shares of AbbVie Inc which is valued at $5,777,604. AbbVie Inc makes up approx 1.83% of Arcadia Investment Management Corpmi’s portfolio.Naples Global Advisors reduced its stake in ABBV by selling 439 shares or 1.53% in the most recent quarter. The Hedge Fund company now holds 28,167 shares of ABBV which is valued at $1,824,377. AbbVie Inc makes up approx 0.73% of Naples Global Advisors’s portfolio.Nn Investment Partners Holdings N.v. reduced its stake in ABBV by selling 30,420 shares or 3.42% in the most recent quarter. The Hedge Fund company now holds 860,235 shares of ABBV which is valued at $55,717,421. AbbVie Inc makes up approx 0.51% of Nn Investment Partners Holdings N.v.’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in ABBV by selling 411,443 shares or 33.52% in the most recent quarter. The Hedge Fund company now holds 815,847 shares of ABBV which is valued at $52,344,744. AbbVie Inc makes up approx 0.23% of Bnp Paribas Arbitrage Sa’s portfolio.
AbbVie Inc opened for trading at $63.57 and hit $63.9 on the upside on Wednesday, eventually ending the session at $63.41, with a gain of 0.14% or 0.09 points. The heightened volatility saw the trading volume jump to 75,02,821 shares. Company has a market cap of $102,557 M.
On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.